Centene Corporation
NYSE:CNCMedical - Healthcare Plans
+$0.67 today
- Market cap
- $33.39B
- Beta
- 1.09
- P/E (TTM)
- -4.7
- EPS (TTM)
- -$13.09
Volume 6.29M
Average 6.16M
CNC Sales of Investments
Cash received from selling or redeeming investments.
Centene CorporationNYSE: CNC
Sales of Investments · Q2 FY2026 · quarter ended Jun 2026
Sales of investments declines year over year
Q2 FY2026 sales of investments of $1.16B fell 8.6% year over year, behind the -1.5% change in trailing-twelve-month sales of investments. Sequentially, it fell 8.9% from the prior quarter. Over 3 fiscal years it compounded at +15.0% a year.
Context
- Sales of investments amounted to 3.0% of revenue in FY2025, down 0.6 pp from a year earlier.
- Sales of investments increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -8.6% toward the trailing-twelve-month pace of -1.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 5.78B USD
- Year-over-year change
- -0.1%
- 4-year CAGR
- +1.4%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.78B | -0.1% |
| FY2024 | 2024-12-31 | 5.79B | +4.7% |
| FY2023 | 2023-12-31 | 5.52B | +45.3% |
| FY2022 | 2022-12-31 | 3.8B | -30.3% |
| FY2021 | 2021-12-31 | 5.46B | — |
Sales of Investments vs competitors
How CNC compares with its peers on the latest reported figures
- CNC's LTM Jun 2026 sales of investments of $5.71B is the 5th largest of the 9 companies compared; the peer median is $2.07B.
- Its year-over-year change of -1.5% is the 5th highest of 9, against a peer median of -16.5%.
- Sales of investments amounts to 2.9% of revenue for CNC, versus a peer median of 3.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $13B | +1.6% | +22.5% | 3.1% | |
| LTM Sep 2026 | $7.83B | -54.8% | -12.6% | 3.9% | |
| LTM Sep 2026 | $6.73B | -132.8% | -68.9% | 1.5% | |
| LTM Sep 2026 | $5.92B | -38.3% | +35.4% | 3.8% | |
| LTM Jun 2026 | $5.71B | -1.5% | +15.0% | 2.9% | |
| LTM Sep 2026 | $2.09B | +50.9% | -13.6% | 0.7% | |
| LTM Jun 2026 | $2.06B | +352.0% | -6.8% | 13.5% | |
| LTM Sep 2026 | $1.41B | +12.3% | +0.2% | 3.2% | |
| LTM Mar 2026 | $72.15M | -34.5% | +215.7% | 1.7% | |
| Peer median (excluding CNC) | $2.07B | -16.5% | -3.3% | 3.2% | |
Competitors are the stored peer set for CNC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 1.34B | 1.2B | 2.7B | 3.29B | (6.68B) |
| Depreciation & Amortization | 1.48B | 1.55B | 1.29B | 1.24B | 1.28B |
| Deferred Income Tax | (132M) | (631M) | (78M) | 13M | (60M) |
| Stock-Based Compensation | 203M | 234M | 216M | 212M | 204M |
| Change in Working Capital | 1.38B | 2.19B | 3.37B | (4.52B) | 823M |
| Accounts Receivables | (2.45B) | (1.63B) | (2.38B) | (4.33B) | 1.48B |
| Inventory | (1.14B) | 0 | 2.12B | 0 | 0 |
| Accounts Payables | 1.14B | 421M | 3.4B | (528M) | (657M) |
| Other Working Capital | 3.83B | 3.4B | 234M | 346M | 0 |
| Other Non-Cash Items | (54M) | 1.71B | 546M | (91M) | 9.52B |
| Operating Cash Flow | 4.21B | 6.26B | 8.05B | 154M | 5.09B |
| Capital Expenditures | (910M) | (1B) | (799M) | (644M) | (767M) |
| Acquisitions (Net) | (466M) | 1.02B | 619M | 990M | (19M) |
| Purchases of Investments | (7.4B) | (6.74B) | (6.62B) | (7.18B) | (4.54B) |
| Sales of Investments | 5.46B | 3.8B | 5.52B | 5.79B | 5.78B |
| Other Investing Activities | 19M | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (3.3B) | (2.92B) | (1.28B) | (1.05B) | 453M |
| Debt Repayment | 1.76B | (1.13B) | 19M | 678M | (1.15B) |
| Common Stock Issued | 0 | 70M | 44M | 46M | 37M |
| Common Stock Repurchased | (297M) | (3.1B) | (1.63B) | (3.12B) | (475M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (102M) | (41M) | 0 | (6M) | (19M) |
| Financing Cash Flow | 1.36B | (4.2B) | (1.57B) | (2.41B) | (1.6B) |
| Effect of Forex Changes | 50M | (187M) | (85M) | 174M | (114M) |
| Net Change in Cash | 2.32B | (1.04B) | 5.12B | (3.13B) | 3.83B |
| Free Cash Flow | 3.3B | 5.26B | 7.25B | (490M) | 4.32B |
Centene Corporation
NYSE:CNC
Intrinsic Alpha fair value
Locked
Current Price
$67.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.